In vitro RHE skin sensitisation assays: Applicability to challenging substances.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 15 05 2019
revised: 30 07 2019
accepted: 04 09 2019
pubmed: 9 9 2019
medline: 27 2 2020
entrez: 9 9 2019
Statut: ppublish

Résumé

In the last 20 years, alternative approaches to the identification of skin sensitisation hazards have been at the forefront of the 3Rs and have helped refine the validation and acceptance processes. However, experience with the local lymph node assay showed that, post-validation, challenges still occurred, particularly when a wider diversity of chemical substances was addressed, a situation which will arise with validated in vitro alternatives. In the present work, a range of substances potentially challenging to assess in current nonanimal OECD test guidelines were evaluated in several of the emerging in vitro alternatives. Twelve such substances (of which just over half were known skin sensitisers) were assessed in 4 assays, all based on reconstructed human epidermis (RHE) models. For hazard identification, the overall predictive accuracy ranged around 70% for three assays, although for one (SensCeeTox), it fell below 50% when human data was used as the benchmark. In most cases, sensitivity was high, such that sensitisation was overpredicted. As the substances were challenging to assess in other nonanimal methods, the results indicate that the 3D RHE models may be a useful tool for assessing skin sensitisation potentials without needing to revert to animal use.

Identifiants

pubmed: 31494190
pii: S0273-2300(19)30237-5
doi: 10.1016/j.yrtph.2019.104473
pii:
doi:

Substances chimiques

Haptens 0
Interleukin-18 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104473

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

A Mehling (A)

BASF Personal Care and Nutrition GmbH, Duesseldorf, Germany.

E Adriaens (E)

Adriaens Consulting BVBA, Aalter, Belgium.

S Casati (S)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

B Hubesch (B)

Hubesch Consult BVBA, Sint-Pieters-Leeuw, Belgium, European Chemical Industry Council (Cefic), Brussels, Belgium.

A Irizar (A)

The International Fragrance Association (IFRA), Geneva, Switzerland.

M Klaric (M)

Cosmetics Europe, Brussels, Belgium.

S Letasiova (S)

MatTek In Vitro Life Science Laboratories, Bratislava, Slovakia.

I Manou (I)

European Partnership for Alternative Approaches to Animal Testing (EPAA), Brussels, Belgium.

B P Müller (BP)

Symrise AG, Holzminden, Germany.

E Roggen (E)

3Rs Management and Consulting ApS, Kongens Lydngby, Denmark.

E van Vliet (E)

Cosmetics Europe, Brussels, Belgium.

D Basketter (D)

DABMEB Consultancy Ltd, Sharnbrook, UK. Electronic address: dabmebconsultancyltd@me.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH